A breakthrough - donanemab has emerged as a significant milestone in the battle against Alzheimer's after a global trial confirmed its ability to slow down cognitive decline. Made by US pharmaceuticals group Eli Lilly, the results of a clinical trial to showcase the findings said antibody treatment slowed progression by about 35 per cent in the early stages of the disease, allowing people with Alzheimer’s to continue performing day-to-day tasks such as shopping, housekeeping, managing their finances and taking medication. , Health News, Times Now
15.06.2023 - Global Trial of Iovance TIL Therapy Lifileucel in Combination with PembrolizumabSAN CARLOS, Calif., June 15, 2023 (GLOBE NEWSWIRE) - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and . Seite 1
/PRNewswire/ Pulnovo Medical Limited, a globally recognized OTM (From Operating Table to Market) innovative platform, today announced the successful close.